Literature DB >> 30284520

Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium.

Ling X Zhang1, Jianfeng Du2, Yu Tina Zhao2, Jianguo Wang2, Shouyan Zhang3, Patrycja M Dubielecka1, Lei Wei4, Shougang Zhuang1, Gangjian Qin5, Y Eugene Chin6, Ting C Zhao2.   

Abstract

Histone deacetylases (HDACs) play a critical role in modulating cardiac function and ischemic injury. HDAC4 was found to be elevated and activated in response to injury. However, whether HDAC4 mediates cardiac function is currently unknown. In this study, we created myocyte-specific activated HDAC4 transgenic mice to examine the role of HDAC4 in mediating cardiac function during development and response to infarction. There are no differences in cardiac function and gross phenotype between wild-type and cardiomyocyte-specific HDAC4 transgenic mice at 1 mo of age. However, cardiac dysfunction and vascular growth deficiency were displayed in 6-mo-old HDAC4-transgenic mice compared with wild-type mice. Activation of HDAC4 increased heart and myocyte size, hypertrophic proteins, and interstitial fibrosis in 6-mo-old mice but not in 1-mo-old mice. To further define whether activated HDAC4 in the heart could impact myocardial function and remodeling, myocardial infarction was created in both wild-type and cardiomyocyte-specific HDAC4-transgenic mice. In myocardial infarction, the overexpression of activated HDAC4 exacerbated cardiac dysfunction and augmented cardiac remodeling and interstitial fibrosis, which was associated with the reduction of cardiokines in the heart. These results indicate the activation of HDAC4 as a crucial regulator for cardiac function in development and myocardial infarction. NEW & NOTEWORTHY We created myocyte-specific activated HDAC4-transgenic mice to examine the function of HDAC4 in mediating cardiac function. HDAC4 overexpression led to cardiac dysfunction, which was associated with increased hypertrophy and myocardial fibrosis. Furthermore, the overexpression of activated HDAC4 exacerbated cardiac dysfunction, augmented remodeling, and increased apoptosis in the infarcted heart. This is the first demonstration that transgenic overexpression of HDAC4 is crucial for modulation of cardiac function and remodeling.

Entities:  

Keywords:  cardiac function and injury; heart; histone deacetylase 4

Mesh:

Substances:

Year:  2018        PMID: 30284520      PMCID: PMC6737459          DOI: 10.1152/japplphysiol.00006.2018

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  33 in total

Review 1.  Signaling to chromatin through histone modifications.

Authors:  P Cheung; C D Allis; P Sassone-Corsi
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis.

Authors:  Ling Zhang; Xin Qin; Yu Zhao; Loren Fast; Shougang Zhuang; Paul Liu; Guangmao Cheng; Ting C Zhao
Journal:  J Pharmacol Exp Ther       Date:  2012-01-23       Impact factor: 4.030

3.  Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells.

Authors:  Matthew LeBoeuf; Anne Terrell; Sohum Trivedi; Satrajit Sinha; Jonathan A Epstein; Eric N Olson; Edward E Morrisey; Sarah E Millar
Journal:  Dev Cell       Date:  2010-11-18       Impact factor: 12.270

4.  Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition.

Authors:  L X Zhang; Y Zhao; G Cheng; T L Guo; Y E Chin; P Y Liu; T C Zhao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

5.  A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p.

Authors:  W Fischle; S Emiliani; M J Hendzel; T Nagase; N Nomura; W Voelter; E Verdin
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Authors:  Ichiro Shiojima; Kaori Sato; Yasuhiro Izumiya; Stephan Schiekofer; Masahiro Ito; Ronglih Liao; Wilson S Colucci; Kenneth Walsh
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.

Authors:  Chun Li Zhang; Timothy A McKinsey; Shurong Chang; Christopher L Antos; Joseph A Hill; Eric N Olson
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

8.  HDAC4 regulates neuronal survival in normal and diseased retinas.

Authors:  Bo Chen; Constance L Cepko
Journal:  Science       Date:  2009-01-09       Impact factor: 47.728

9.  Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice.

Authors:  Anne Granger; Ibrahim Abdullah; Faith Huebner; Andrea Stout; Tao Wang; Thomas Huebner; Jonathan A Epstein; Peter J Gruber
Journal:  FASEB J       Date:  2008-07-07       Impact factor: 5.191

10.  HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1.

Authors:  Ting C Zhao; Jianfeng Du; Shougang Zhuang; Shugang Zhuang; Paul Liu; Ling X Zhang
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

View more
  10 in total

1.  Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.

Authors:  Wei Zhang; Yinjie Guan; George Bayliss; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2020-10-05

Review 2.  The role of histone deacetylase 4 during chondrocyte hypertrophy and endochondral bone development.

Authors:  Zhi Chen; Zhiwei Zhang; Li Guo; Xiaochun Wei; Yang Zhang; Xiaojian Wang; Lei Wei
Journal:  Bone Joint Res       Date:  2020-05-16       Impact factor: 5.853

Review 3.  Epigenetic Biomarkers in Cardiovascular Diseases.

Authors:  Carolina Soler-Botija; Carolina Gálvez-Montón; Antoni Bayés-Genís
Journal:  Front Genet       Date:  2019-10-09       Impact factor: 4.599

Review 4.  HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.

Authors:  Xing Lyu; Min Hu; Jieting Peng; Xiangyu Zhang; Yan Y Sanders
Journal:  Ther Adv Chronic Dis       Date:  2019-07-18       Impact factor: 4.970

Review 5.  Targeting Epigenetics and Non-coding RNAs in Myocardial Infarction: From Mechanisms to Therapeutics.

Authors:  Jinhong Chen; Zhichao Liu; Li Ma; Shengwei Gao; Huanjie Fu; Can Wang; Anmin Lu; Baohe Wang; Xufang Gu
Journal:  Front Genet       Date:  2021-12-20       Impact factor: 4.599

6.  microRNA-124-3p attenuates myocardial injury in sepsis via modulating SP1/HDAC4/HIF-1α axis.

Authors:  Mei Wu; Zehong Huang; Wenfang Huang; Mengyu Lin; Weifeng Liu; Kexuan Liu; Cai Li
Journal:  Cell Death Discov       Date:  2022-01-28

Review 7.  Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis.

Authors:  Jingrong Shao; Jiao Liu; Shengkai Zuo
Journal:  Cells       Date:  2022-07-30       Impact factor: 7.666

8.  Correlation of the prognostic value of FNDC4 in glioblastoma with macrophage polarization.

Authors:  Hongwu Li; Xiaofei Yan; Shaowu Ou
Journal:  Cancer Cell Int       Date:  2022-09-02       Impact factor: 6.429

9.  Interactions between the ERK1/2 signaling pathway and PCAF play a key role in PE‑induced cardiomyocyte hypertrophy.

Authors:  Qian Mao; Shuqi Wu; Chang Peng; Bohui Peng; Xiaomei Luo; Lixin Huang; Huanting Zhang
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

Review 10.  Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy.

Authors:  Xiangyu Ke; Zhirui Lin; Zebing Ye; Meifang Leng; Bo Chen; Chunjie Jiang; Xiaoyun Jiang; Guowei Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.